<DOC>
	<DOCNO>NCT03023787</DOCNO>
	<brief_summary>To evaluate safety tolerability Hepalatide ( L47 ) characterize clinical pharmacokinetics healthy volunteer .</brief_summary>
	<brief_title>Study Hepalatide ( L47 ) Phase Ib Healthy Volunteers</brief_title>
	<detailed_description>This randomize , double-blinded , dose escalating , phase Ib trial , conduct No . 302 Hospital China . There three cohort dose 4.2mg , 6.3mg 8.4mg . All healthy volunteer randomize Hepalatide placebo group 4:1 rate , healthy volunteer receive treatment drug abdominal subcutaneous injection day seven day observe 3 day .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Ages 18 45 year BMI Index 19 25 ( BMI=weight/height2 ) Normal previous history physical exam No drug alcohol abuse No illness 4 week drug therapy 2 week No blood donation subject sample 3 month Consistent correct use recommend method birth control men woman Good compliance study protocol Understand agree sign consent form Infection HAV , HBV , HCV , HEV , HIV , EBV CMV Abnormal clinical significance test physical examination , vital sign , blood routine , urine routine , liver kidney function , coagulation indicator , electrolyte , glucose , blood lipid , thyroid function , chest XRay , ECG , B ultrasound gallbladder , spleen kidney , AFP , CEA Positive antiPreS1 antibody Women pregnant nursing , abnormal sex hormone , B ultrasound ovaries/uterus proliferative disease breast mass Unable quit smoke trial Subject little chance enrollment ( i.e . weak ) Subject suitable join trial circumstance judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>